12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Apremilast: Phase III data

Top-line data from the double-blind, international Phase III PALACE-1 trial in about 500 patients showed that twice-daily 20 and 30 mg oral apremilast each met the primary endpoint of improving the proportion of patients achieving an ACR20 response at week 16 vs. placebo. High-dose apremilast also met the secondary endpoints of improving ACR50 and ACR70 response rates at week 24 vs. placebo. Low-dose apremilast met the ACR50 endpoint, but missed the...

Read the full 332 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >